More recent studies have indicated that patients who receive neoadjuvant CRT followed by adjuvant nivolumab in the presence of residual tumor experience improved disease-free survival (DFS), irrespective of their pretherapeutic PD-L1 combined positive score (CPS) (6). The gene discussed is CD274; the disease is neoplasm.